{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116348","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.166066+00:00","generated_at":"2026-06-08T06:29:12.968610+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immunome completes Morphimmune merger, $125M PIPE, Q3 net loss $4M","bullets":["Completed merger with Morphimmune; concurrent $125M oversubscribed PIPE from Enavate Sciences, EcoR1 Capital, Redmile, Janus Henderson, Avidity, Woodline.","Clay B. Siegall (ex-Seagen CEO) appointed Chairman & CEO; Bob Lechleider as CMO; Jean-Jacques Bienaimé (ex-BioMarin CEO) to board.","Q3 collaboration revenue $4M from AbbVie; R&D and G&A each $4M; net loss $4M ($0.36 per share); cash $91M as of Sept 30.","Cash runway extended into Q1 2026; expect IMM-ONC-01 IND guidance Q1 2024; 177Lu-FAP IND submission Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116348","json":"https://secwatch.observer/filing/0001104659-23-116348.json","markdown":"https://secwatch.observer/filing/0001104659-23-116348.md","text":"https://secwatch.observer/filing/0001104659-23-116348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923116348/0001104659-23-116348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923116348/tm2330142d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:29:12.968610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fcd07e7cd17275ee518e791b47e322e4409eab45","claim":"Immunome Inc. reported the third quarter ended September 30, 2023 results: revenue $4 million, net income Net loss ... was $4 million, or $(0.36) per share, EPS $(0.36) per share.","evidence_excerpt":"in Q1 2025. Financial Highlights · Collaboration Revenue: Collaboration Revenue from the Collaboration Agreement with AbbVie for the three months ended September 30, 2023 was $4 million. · Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2023 were $4 million. · General and administrative (G&A) expenses: G&A expenses","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923116348/0001104659-23-116348-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$4 million"},{"label":"Net income","value":"Net loss ... was $4 million, or $(0.36) per share"},{"label":"EPS","value":"$(0.36) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}